

ASX ANNOUNCEMENT

ASX: 1AI | 30 March 2026

Algorae Pharmaceuticals Partners with Peter MacCallum Cancer Centre for Second AI-driven Drug Synergy Screening Program

Highlights

- Algorae Pharmaceuticals has entered into an agreement with the Victorian Centre for Functional Genomics ("VCFG") at Peter MacCallum Cancer Centre for a second program to independently validate predictions generated by AlgoraeOS v2 ("AOS2").
- Twenty-four high-priority drug combination candidates will be screened for synergy across four cancer cell lines, including glioblastoma, rhabdomyosarcoma, melanoma and chronic myelogenous leukaemia.
- The project is expected to generate key preclinical data within six months, accelerating the Company's pipeline development.

Algorae Pharmaceuticals Ltd (ASX: 1AI) ("Algorae" or "the Company") has entered into an agreement with the **Victorian Centre for Functional Genomics** ("VCFG") at **Peter MacCallum Cancer Centre** ("Peter Mac") for a second program to independently validate the predictions from AlgoraeOS version 2 ("AOS2").

As announced 12 December 2025, Algorae completed a preliminary examination of the AOS2 prediction set. Using pre-specified prioritisation thresholds that balance the magnitude of predicted synergy with uncertainty reduction and biological generalisability, the Company identified 90 potential drug combination candidates. Following analysis of commercial and intellectual property considerations, **24 high-priority drug combination candidates** have been selected for preclinical validation.

Under the agreement, VCFG will perform compound synergy interaction screens using its high-throughput technologies and synergy assessment methodologies. The collaboration is designed to evaluate the predicted synergy of drug combinations across four distinct cancer cell lines: glioblastoma, rhabdomyosarcoma and chronic myelogenous leukaemia and melanoma.

Commenting on the collaboration, Algorae Chief Scientific Officer, **Dr James McKenna** said:

"We are excited to be building on the foundations of our initial work with the VCFG team at the Peter MacCallum Cancer Centre. This program represents an important step in the development of AOS2 as we continue to bridge the gap between in silico prediction and biological validation."

AlgoraeOS v2

As announced 12 December 2025 and 10 November 2025, the AOS2 prediction set comprises CBD in combination with more than 3,000 approved and investigational drugs, evaluated across 170 cell lines, representing in aggregate more than 500,000 potential CBD-drug-cell line combinations.

AOS2 outperformed representative state-of-the-art models, including those from Google DeepMind, and demonstrated stronger calibration across biologically diverse, clinically relevant synergy regions. AOS2 predictions span the full spectrum of interaction from strong agonism to strong synergy and provide additional granularity across each of the four well-recognised synergy metrics (ZIP, Bliss, HSA and Loewe).

Each prediction is associated with confidence-weighted outputs which quantify both data-driven and model-driven uncertainty, enabling risk-aware prioritisation of every synergy prediction. These advanced metrics provide additional tools to scrutinise and refine candidate selection.

Algorae has now completed a preliminary examination of the AOS2 predictions. Using pre-specified prioritisation thresholds that balance the magnitude of predicted synergy with uncertainty reduction and biological generalisability, the Company will evaluate 24 drug candidates using VCFG's advanced screening platform, which includes high-throughput technologies and synergy assessment methodologies. The collaboration is designed to confirm the efficacy of drug combinations across four distinct cancer cell lines.

Strategic Importance

The partnership with VCFG is an important step in validating Algorae's AI-driven approach to drug discovery. The Algorae Operating System ("AlgoraeOS"), developed in collaboration with the UNSW AI Institute and supported by CSIRO funding, has predicted these novel drug interactions. This preclinical screening program will empirically test the AOS2 predictions and provide essential data to support regulatory and commercial pathways.

Executive Chairman, **Mr David Hainsworth** commented:

"This second agreement with Peter Mac marks another significant milestone for Algorae. AlgoraeOS v2 represents a major advancement in our AI prediction capabilities, and we are delighted to collaborate again with Australia's premier cancer research institution on this validation program."

Study Design and Timeline

The screening process, performed in collaboration with VCFG at Peter Mac, will include:

- Optimising cell growth conditions for high-throughput drug screening
- Quantifying treatment effects using microscopy and Chemiluminescence viability assays.
- Generating single-agent dose-response curves across four cancer cell lines.
- Conducting synergy screens using selected dose ranges.

Data analysis will be completed within three weeks of each screen run, with the full dataset expected within six months. Key decision points will be integrated into the study to ensure data quality and optimise further testing.

Commercial and Development Implications

Successful validation of these AI-predicted drug combinations could significantly de-risk their further development.

Positive outcomes from the Peter Mac collaboration may support:

- Internal advancement of selected candidates towards clinical studies.
- Out-licensing or partnership opportunities with other pharmaceutical companies.
- Expansion of the AI-driven discovery pipeline into additional therapeutic areas.

About Peter MacCallum Cancer Centre

Peter MacCallum Cancer Centre is a world-leading cancer research, education and treatment centre and Australia's only public health service solely dedicated to caring for people affected by cancer. The Victorian Centre for Functional Genomics was established over 16 years ago and is an internationally recognised technology platform (co-supported by Phenomics Australia, a National Collaborative Research Infrastructure Strategy consortia) that enables advanced high throughput screens using gene and drug targeting strategies coupled with innovative image analytics.

Peter Mac currently treats more than 47,000 patients every year, combining care and compassion with the latest research to deliver best possible treatments, care and outcomes for patients. This care is matched with world-class facilities within the Parkville Biomedical Precinct and at six additional metropolitan and regional campuses.

<https://www.petermac.org>

Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd

END.

Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: inquiries@algoraepharma.com


About Algorae Pharmaceuticals

Algorae Pharmaceuticals Ltd (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies artificial intelligence to identify synergistic drug combinations and inform preclinical experimental design.

In parallel, Algorae operates a commercialisation business, AlgoraeRx, which sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels. Algorae collaborates with research institutions and industry partners to translate AI-predicted therapies and expand patient access to high-quality medicines. For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.



ALGORAE
PHARMACEUTICALS

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.